Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe SepsisEdward Abraham, Abla A. Creasey, Konrad Reinhart et al.|JAMA|2003Cited by 958
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*Jean‐Louis Vincent, Jonathan Janes, Gordon R. Bernard et al.|Critical Care Medicine|2005Cited by 321
Recombinant Tissue Factor Pathway Inhibitor in Severe Community-acquired Pneumonia: A Randomized TrialRichard G. Wunderink, Steven M. Opal, Pierre-François Laterre et al.|American Journal of Respiratory and Critical Care Medicine|2011Cited by 128
Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)Peter Pickkers, Derek C. Angus, Kristie Bass et al.|Intensive Care Medicine|2024Cited by 67
Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injuryPeter Pickkers, Anne Louise Kjølbye, Derek C. Angus et al.|BMJ Open|2023Cited by 17